In 2020, Christopher K. Mirabelli, Ph.D. earned $602.34K in total compensation at Leap Therapeutics, Inc., including $400.00K salary and $168.00K bonus. Most recently acquired 571,428 shares in Feb 2019. Currently holds stock worth $4.60M. Led Leap Therapeutics, Inc. as CEO for 3 years.
Compensation History
Annual executive compensation data for Christopher K. Mirabelli, Ph.D., including salary, bonuses, and stock awards.
Year
2020
Total Compensation
$602.34K
Salary
$400.00K
Bonus
$168.00K
Other
$34.34K
Salary
$400.00KBoard Justification
The compensation program is designed to attract and retain a highly skilled team of key executives and align their compensation with the interests of stockholders by rewarding the achievement of strategic financial goals.
Bonus
$168.00KBoard Justification
Cash bonus equal to 120% of the target bonus amount based on the achievement of corporate objectives established by the Board.
Other Compensation
$34.34KBoard Justification
Other compensation includes 401(k) matching, medical and dental insurance, life insurance, and paid medical leave.
Restricted Stock
Board Justification
No stock vested in 2020 as he stepped down as CEO on April 1, 2020.
Performance Metrics
The performance metrics for determining the compensation included achievement of corporate objectives established by the Board.
Christopher K. Mirabelli, Ph.D.
Ex-CEO of Leap Therapeutics, Inc.
Education
Ph.D. in Biomedical Engineering
Field of Expertise
Healthcare & Life Sciences - Biomedical
Sector of Economy
Healthcare
Born
January 1, 1958 - 67 years ago
CEO of Leap Therapeutics, Inc. for
3 years 7 months (Aug 2016 - Apr 2020)
Previous Experience
President and Chief Executive Officer of Leap Therapeutics, Inc.
Other Leap Therapeutics, Inc. CEOs
Holdings
Track Christopher K. Mirabelli, Ph.D.'s stock holdings and portfolio value over time.
Insider Trading
Christopher K. Mirabelli, Ph.D.'s recent stock transactions, purchases, and sales filed with the SEC.
$1.00M
LPTX at $1.75/share
Feb 5, 2019
Purchase
$6.44M
LPTX at $6.09/share
Nov 14, 2017
Purchase
Rivals
Compare Christopher K. Mirabelli, Ph.D. with competitor CEOs and industry peers.